Yvonne Saenger
Co-Leader, Cancer Therapeutics, Montefiore Einstein Comprehensive Cancer Center · Montefiore Medical Center/Albert Einstein College of Medicine
Credentials: · · · ·
History
PresentCancer Therapeutics · Montefiore Medical Center/Albert Einstein College of Medicine
- Present
Immune Monitoring Core Facility · Montefiore Medical Center/Albert Einstein College of Medicine
- Present
Albert Einstein Cancer Center and Montefiore Cancer Immunotherapy Program · Montefiore Medical Center/Albert Einstein College of Medicine
2001–2004
Research
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
Nature Medicine · 2019 · 762 citations
The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation
Review · The Oncologist · 2008 · 201 citations
European Radiology · 2020 · 137 citations
19 papers
14 papers
- BH
9 papers
- RC
9 papers · 3 as a resident
9 papers · 2 as a resident
8 papers · 4 as a fellow
- MT
8 papers
- IO
6 papers
Grants
- 2023–2028
Montefiore Einstein Clinical Oncology Training Program in the Bronx
National Cancer Institute · K12
PI · $2.1M · Albert Einstein College of Medicine
- 2021–2027
Applying Pathomics to Establish a Biosignature for Aggressive Skin Melanoma
National Cancer Institute · R01
Contact PI · $3.1M · Albert Einstein College of Medicine
- 2019–2025
A Prognostic mRNA Immune Signature for Resected Stage II-III Melanoma
National Cancer Institute · UH3
Contact PI · $1.1M · Albert Einstein College of Medicine
- 2018–2022
Ph1 Study of T-Vec Given Endoscopically for Advanced Pancreatic Cancer IN 17248 (11/21/2016)
Food and Drug Administration · R01
Contact PI · $750K · Columbia University Health Sciences
Clinical trials
- 2015–2022
MRI and PET to Assess Pembrolizumab Response
Principal investigator · Terminated · Early phase 1
Columbia University